Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: Diagnosis value, associations with radiological progression rate, and extra-articular manifestations

Annals of the Rheumatic Diseases

Volumn 63, Issue 12, 2004, Pages 1587-1593

  De Rycke, L ^a   Peene, I ^a   Hoffman, I E A ^a   Kruithof, E ^a   Union, A ^b   Meheus, L ^b   Lebeer, K ^b   Wyns, B ^d   Vincent, C ^c   Mielants, H ^a   Boullart, L ^d   Serre, G ^c   Veys, E M ^a   De Keyser, F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b INNOGENETICS   (Belgium)

^c INSERM   (France)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CITRULLINATED PROTEIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SERODIAGNOSIS; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CITRULLINE; DISEASE PROGRESSION; EPITOPES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RHEUMATOID FACTOR; RHEUMATOID NODULE; SENSITIVITY AND SPECIFICITY; VASCULITIS;

EID: 7044279878     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.017574     Document Type: Article

References (34)

1. Arnett FC, Edworthy SM, Bloch DA McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
2. Vincent C, De Keyser F, Masson-Bessière C, Sebbag M, Veys EM, Serre G. Antiperinuclear factor compared with the so called antikeratin antibodies and antibodies to human epidermal filaggrin, in the diagnosis of arthritides. Ann Rheum Dis 1999;58:42-8.
3. Vincent C, Simon M, Sebbag M, Girbal-Neuhauser E, Durieux JJ, Cantagrel A, et al. Immunoblotting detection of autoantibodies to human epidermis filaggrin: a new diagnostic test for rheumatoid arthritis. J Rheumatol 1998;25:838-46.
4. Nogueira L, Sebbag M, Vincent C, Arnaud M, Fournie B, Cantagrel A, et al. Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis. Ann Rheum Dis 2001;60:882-7.
5. Vincent C, Nagueira L, Sebbag M, Chapuy-Regaud S, Arnaud M, Letourneur O, et al. Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay. Arthritis Rheum 2002;46:2051-8.
6. Union A, Meheus L, Humbel R, Conrad K, Steiner G, Moereels H, et al. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum 2002;46:1185-95.
7. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
8. Girbal-Neuhauser E, Durieux J-J, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999;162:585-94.
9. Schellekens GA, Visser H, de Jong BAW, van den Hoogen FHJ, Hazes JMW, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
10. Bizarro N, Mazzanti G, Tonutti E, Villalta D, Tozolli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001;47:1089-93.
11. Vossenaar ER, van Venrooij WJ, Pruijn CJM. Anti-CCP antibodies in (early) rheumatoid arthritis. In: Conrad K, Fritzler M, Meurer M, Sack U, Shoenfeld Y, eds. From proteomics to molecular epidemiology: relevance of autoantibodies: report on the 6th Dresden symposium held in Dresden, September 4-7 2002:454-02.
12. Suzuki K, Sawada T, Murakami A, Matsui T, Tohma S, Nakazono K, et al. Yamamoto K. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003;32:197-204.
13. Harrison B, Thomson W, Symmons D, Ollier B, Wiles N, Payton T, et al. The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis. Arthritis Rheum 1999;42:2174-83.
14. Moreno I, Valenzuela A, Garcia A, Yelamos J, Sanchez B, Hernanz W. Association of the shared epitope with radiological severity of rheumatoid arthritis. J Rheumatol 1996;23:6-9.
15. Paimela L, Leirisalo-Repo M, Helve T, Koskimies S. The prognostic value of HLA DR4 and B27 antigens in early rheumatoid arthritis. Scand J Rheumatol 1993;22:220-4.
16. Hulsmans HMJ, Jacobs JWG, Van Der Heijde D, Van Albada-Kuipers GA, Schenk Y, Bijlsma JWJ. The course of radiological damage during me first six years of rheumatoid arthritis. Arthritis Rheum 2000;43:1927-40.
17. Sharp JT, Wolfe F, Mitchell DM, Bloch DA. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 1991;34:660-8.
18. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis. Arthritis Rheum 1998;41:1571-82.
19. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000;343:1594-002.
20. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44:1984-92.
21. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarbora C, Smolen JS, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-43.
22. Van Jaarsveld CHM, ter Borg EJ, Jacobs JWG, Schellekens GA, Gmelig-Meyling FHJ, van Booma-Frankfort C, et al. The prognostic value of the anti-perinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheum 1999; 17:689-97.
23. Jansen ALMA, van der Horst-Bruinsma IE, van Schaardenburg D, van de Stadt RJ, de Koning MHMT, Dijkmans BAC. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002;29:2074-6.
24. Plant MJ, Jones PW, Saklatvala J, Ollier WER, Dawes PT. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol 1998;25:417-26.
25. Kroot EJ, De Jong BAW, Van Leeuwen MA, Swinkels H, Van den Hoogen FHJ, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
26. Bas S, Perneger TV, Mikhnevitch E, Seitz M, Tiercy JM, Roux-Lombard P, et al. Associations of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis. Rheumatology 2000;39:1082-8.
27. Aho K, Palosuo T, Lukka M, Kurki P, Isomaki H, Kautiainen H, et al. Anti-filaggrin antibodies in recent onset arthritis. Scand J Rheumatol 1999;28:113-16.
28. Kaltenhäuser S, Wagner U, Schuster E, Wassmuth R, Arnold S, Seidel W, et al. Immunogenetic markers and seropositivity predict radiological progression in early rheumatoid arthritis independent of disease activity. J Rheumatol 2001;28:735-44.
29. Mattey DL, Hassell AB, Dawes PT, Cheung NT, Poulton KV, Thomson W, et al. Independent association of rheumatoid factor and the HLA-DRB1 Shared epitope with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2001;44:1529-33.
30. Meyer O, Labarre C, Dougados M, Goupille Ph, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6.
31. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, Ruzickova S. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427-30.
32. Smolen JS. Autoantibodies in rheumatoid arthritis. In: Van Venrooij WJ, Maini RN, eds. Manual of biological markers of disease. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1996;C1:1, 1-18.
33. German JD, Criswell LA. The shared epitope and severity of rheumatoid arthritis. Rheum Dis Clin North Am 2002;28:59-78.
34. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairins E. Cutting edge: the conversion of arginine to citrulline allows for a high affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;171:538-41.